Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory bowel disease
Pharma
J&J pads Tremfya IBD offerings with subQ ulcerative colitis nod
With a fresh FDA nod, J&J has rounded out Tremfya’s presence in inflammatory bowel disease and achieved a first for the IL-23 inhibitor drug class.
Fraiser Kansteiner
Sep 22, 2025 11:01am
J&J's Tremfya picks up key FDA nod in Crohn's disease
Mar 20, 2025 7:56pm
As IBD sales boom, AbbVie increases Skyrizi, Rinvoq projection
Jan 31, 2025 11:41am
Lilly's Omvoh bests J&J's Stelara in Crohn's study
Oct 14, 2024 12:15pm
Tremfya enters crowded ulcerative colitis arena with FDA nod
Sep 11, 2024 6:58pm
AbbVie-FutureGen, Takeda, Kyowa Kirin—Fierce Pharma Asia
Jun 14, 2024 5:00am
